Fate Therapeutics Inc (FATE)
3.57
+0.07
(+2.00%)
USD |
NASDAQ |
Sep 27, 16:00
3.575
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Research and Development Expense (Annual): 172.60M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 172.60M |
| December 31, 2022 | 320.45M |
| December 31, 2021 | 215.52M |
| December 31, 2020 | 125.62M |
| December 31, 2019 | 87.77M |
| December 31, 2018 | 56.02M |
| December 31, 2017 | 34.36M |
| Date | Value |
|---|---|
| December 31, 2016 | 26.45M |
| December 31, 2015 | 19.86M |
| December 31, 2014 | 16.44M |
| December 31, 2013 | 12.01M |
| December 31, 2012 | 12.00M |
| December 31, 2011 | 9.858M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
87.77M
Minimum
2019
320.45M
Maximum
2022
184.39M
Average
172.60M
Median
2023
Research and Development Expense (Annual) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.31M |
| Oragenics Inc | 15.49M |